Sigal Charles Elliott — SEC insider filings
SEC reporting owner CIK 1661908. 22 insider filings on record with FilingPulse; latest filed 2026-11-12.
Transaction summary — filings shown
Covers all 22 filings on record, filed 2020-10-13 to 2026-11-12. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 5 legs across 4 filings — 11,600 shares, $489,940 total (shares × price as filed).
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 27.
- Largest priced transaction: purchase of 1,600 shares @ $152.25 ($243,600) in ALNYLAM PHARMACEUTICALS, INC., filed 2026-11-12.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | Director | 10 | 4 legs · 10,000 sh · $246,340 | — | 13 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Director | 6 | 1 leg · 1,600 sh · $243,600 | — | 7 |
| Surface Oncology, Inc. (SURF) | Director | 3 | — | — | 4 |
| Adaptimmune Therapeutics PLC (ADAP) | Director | 3 | — | — | 3 |
Insider filings — Sigal Charles Elliott
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-11-12 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Purchase (P): 1,600 @ $152.25 | EDGAR |
| 2026-05-28 | 4 | Vir Biotechnology, Inc. (VIR) | Grant/award (A): 8,000 @ $0 · Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2026-05-22 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 671 @ $0 · Grant/award (A): 1,441 (derivative) @ $0 | EDGAR |
| 2025-06-02 | 4 | Vir Biotechnology, Inc. (VIR) | Grant/award (A): 8,000 @ $0 · Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2025-05-12 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 775 @ $0 · Grant/award (A): 1,558 (derivative) @ $0 | EDGAR |
| 2024-06-03 | 4 | Vir Biotechnology, Inc. (VIR) | Grant/award (A): 8,000 @ $0 · Grant/award (A): 16,000 (derivative) @ $0 | EDGAR |
| 2024-05-20 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 5,228 (derivative) @ $0 | EDGAR |
| 2023-09-08 | 4 | Surface Oncology, Inc. (SURF) | Disposition to issuer (D): 45,453 · Disposition to issuer (D): 113,636 (derivative) @ $0 | EDGAR |
| 2023-07-03 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Grant/award (A): 933,317 (derivative) @ $0 | EDGAR |
| 2023-05-24 | 4 | Vir Biotechnology, Inc. (VIR) | Grant/award (A): 6,027 @ $0 · Grant/award (A): 12,054 (derivative) @ $0 | EDGAR |
| 2023-05-19 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 3,454 (derivative) @ $0 | EDGAR |
| 2023-03-02 | 4 | Vir Biotechnology, Inc. (VIR) | Purchase (P): 2,500 @ $22.73 | EDGAR |
| 2023-01-09 | 4 | Vir Biotechnology, Inc. (VIR) | Purchase (P): 2,500 @ $24.96 | EDGAR |
| 2023-01-05 | 4 | Vir Biotechnology, Inc. (VIR) | Purchase (P): 2,500 @ $25.60 · Purchase (P): 2,500 @ $25.25 | EDGAR |
| 2022-08-24 | 4 | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | Grant/award (A): 4,456 (derivative) @ $0 | EDGAR |
| 2022-07-01 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Grant/award (A): 737,050 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | Surface Oncology, Inc. (SURF) | Grant/award (A): 24,000 (derivative) @ $0 | EDGAR |
| 2022-05-25 | 4 | Vir Biotechnology, Inc. (VIR) | Grant/award (A): 6,405 @ $0 · Grant/award (A): 12,810 (derivative) @ $0 | EDGAR |
| 2021-07-02 | 4 | Adaptimmune Therapeutics PLC (ADAP) | Grant/award (A): 474,385 (derivative) @ $0 | EDGAR |
| 2021-06-10 | 4 | Surface Oncology, Inc. (SURF) | Grant/award (A): 17,700 (derivative) @ $0 | EDGAR |
| 2021-05-25 | 4 | Vir Biotechnology, Inc. (VIR) | Grant/award (A): 3,374 @ $0 · Grant/award (A): 6,748 (derivative) @ $0 | EDGAR |
| 2020-10-13 | 4/A | Vir Biotechnology, Inc. (VIR) | Grant/award (A): 28,394 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-10-09 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1661908 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs